Shodiyev Asliddin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shodiyev Asliddin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Ali G. Alkhathami
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
1 shared publication- Amera Bekhatroh Rashed
Nursing Department, College of Applied Medical Sciences, Jouf University, Saudi Arabia
1 shared publication Ashok Kumar Bishoyi
Department of Microbiology, Faculty of Science, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, 360003, India
1 shared publication- Bahaa Ibrahim Saeed
Medical Laboratory Techniques Department, College of Health and Medical Technology, University of Al-maarif, Anbar, Iraq
1 shared publication - Deepak Bhanot
Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, India
1 shared publication Deepak Nathiya
Department of Pharmacy Practice, NIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur, India
1 shared publication
Latest Publications
- Open Access
- 10 October 2026
- Published by Kokand State Pedagogical Institute in Qo‘qon DPI. Ilmiy xabarlar jurnali
- Vol. 8 (9) , 2194-2201
POLIURETAN CHIQINDILARINI IKKI BOSQICHLI MAYDALASH TEXNOLOGIYASINI TAKOMILLASHTIRISH VA TEXNOLOGIK PARAMETRLARINI TADQIQ QILISH
Ushbu maqolada poliuretan chiqindilarini mexanik, fizik-kimyoviy va kompozitsion qayta ishlashga tayyorlash uchun ikki bosqichli maydalash texnologiyasi ishlab chiqish va optimal texnologik parametrlari tadqiq qilindi. Tadqiqotda rotor-pichoqli maydalagich konstruksiyasi va uning texnik ko‘rsatkichlari asos qilinib chiqindini dastlabki tayyorlashda 150 - 200 mm o‘lchamli yirik bo‘laklar shakllantiriladi, birinchi bosqichda kesish - siqish mexanizmi asosida o‘lcham nazorat qilinadi, ikkinchi bosqichda esa 50 - 55 mm fraksiyagacha maydalash tavsiya etiladi. Manbada keltirilgan rotor-pichoqli qurilma uchun unumdorlik 100-300 kg/soat, rotor aylanish tezligi 500 - 800 ayl/min, elektr dvigatel quvvati 7,5 - 11 kW, yuklash bunkeri 800×600 mm, chiqish fraksiyasi 10-30 mm, umumiy o‘lchamlari 1800×1000×1450 mm va massasi taxminan 650 kg deb berilgan. Xalqaro adabiyotlar tahlili mexanik maydalash PU chiqindilarini qayta ishlashning eng sodda va iqtisodiy jihatdan maqbul boshlang‘ich bosqichlaridan biri ekanini, zarracha o‘lchami esa keyingi qayta ishlash usulining samaradorligini belgilovchi asosiy parametr ekanini ko‘rsatadi.
- 10 October 2026
- Published by Kokand State Pedagogical Institute in Qo‘qon DPI. Ilmiy xabarlar jurnali
- Vol. 8 (9) , 2194-2201
Open AccessPOLIURETAN CHIQINDILARINI IKKI BOSQICHLI MAYDALASH TEXNOLOGIYASINI TAKOMILLASHTIRISH VA TEXNOLOGIK PARAMETRLARINI TADQIQ QILISH
Ushbu maqolada poliuretan chiqindilarini mexanik, fizik-kimyoviy va kompozitsion qayta ishlashga tayyorlash uchun ikki bosqichli maydalash texnologiyasi ishlab chiqish va optimal texnologik parametrlari tadqiq qilindi. Tadqiqotda rotor-pichoqli maydalagich konstruksiyasi va uning texnik ko‘rsatkichlari asos qilinib chiqindini dastlabki tayyorlashda 150 - 200 mm o‘lchamli yirik bo‘laklar shakllantiriladi, birinchi bosqichda kesish - siqish mexanizmi asosida o‘lcham nazorat qilinadi, ikkinchi bosqichda esa 50 - 55 mm fraksiyagacha maydalash tavsiya etiladi. Manbada keltirilgan rotor-pichoqli qurilma uchun unumdorlik 100-300 kg/soat, rotor aylanish tezligi 500 - 800 ayl/min, elektr dvigatel quvvati 7,5 - 11 kW, yuklash bunkeri 800×600 mm, chiqish fraksiyasi 10-30 mm, umumiy o‘lchamlari 1800×1000×1450 mm va massasi taxminan 650 kg deb berilgan. Xalqaro adabiyotlar tahlili mexanik maydalash PU chiqindilarini qayta ishlashning eng sodda va iqtisodiy jihatdan maqbul boshlang‘ich bosqichlaridan biri ekanini, zarracha o‘lchami esa keyingi qayta ishlash usulining samaradorligini belgilovchi asosiy parametr ekanini ko‘rsatadi.
- 25 September 2026
- Published by Science Algorithm in Journal of Advances in Engineering Technology
- Vol. 3 (23)
ТЕРМОРЕАКТИВ ПОЛИУРЕТАНЛАРНИНГ ПОЛИКОНДЕНСАЦИЯЛАНИШ ЖАРАЁНИДА ҲОСИЛ БЎЛАДИГАН ГАЗЛАРНИ АЖРАТИБ ОЛИШ ҚУРИЛМАСИНИ ҚЎЛЛАШНИ ТАДҚИҚ ҚИЛИШ
Мазкур мақолада суюқ полиуретан таркибида мавжуд ҳаво, намлик ва реакция жараёнида ҳосил бўладиган газларни самарали ажратиб олиш учун вакуумли дегазация қурилмасини қўллаш технологияси тадқиқ қилинган. Тадқиқотларда полиуретан композицияси 60 80 °С ҳароратда 250–400 айл/мин тезликда 10–20 дақиқа давомида аралаштирилиб, кейин 0,085 0,095 МПа вакуум остида 15–30 дақиқа дегазация қилинди. Дегазация жараёнида полиуретан таркибидаги газ пуфакчалари ҳажми 92–97 % га камайиши, зичликнинг 1,08–1,12 г/см³ дан 1,14–1,18 г/см³ гача ортиши ҳамда ғовакликнинг 6,8 % дан 1,2 % гача пасайиши аниқланди. Шунингдек, дегазация жараёнидан сўнг таёрланган полиуретан материалининг Shore A/D қаттиқлиги 78/22 бирликдан 88/26 бирликкача, чўзилишдаги мустаҳкамлиги 18–22 МПа дан 28–34 МПа гача, нисбий ейилишга чидамлилиги эса 20–30 % га ошиши кузатилди. Олинган натижалар вакуумли дегазация қурилмасини қўллаш полиуретан маҳсулотларининг ички структурасини яхшилаши, ғоваклар ва ички нуқсонларни кескин камайтириши, қуйиш жараёнининг барқарорлигини ошириши ҳамда юқори мустаҳкам ва узоқ муддат хизмат қилувчи полиуретан буюмларини ишлаб чиқариш учун самарали технология эканлигини кўрсатди.
- 25 September 2026
- Published by Science Algorithm in Journal of Advances in Engineering Technology
- Vol. 3 (23)
ТЕРМОРЕАКТИВ ПОЛИУРЕТАНЛАРНИНГ ПОЛИКОНДЕНСАЦИЯЛАНИШ ЖАРАЁНИДА ҲОСИЛ БЎЛАДИГАН ГАЗЛАРНИ АЖРАТИБ ОЛИШ ҚУРИЛМАСИНИ ҚЎЛЛАШНИ ТАДҚИҚ ҚИЛИШ
Мазкур мақолада суюқ полиуретан таркибида мавжуд ҳаво, намлик ва реакция жараёнида ҳосил бўладиган газларни самарали ажратиб олиш учун вакуумли дегазация қурилмасини қўллаш технологияси тадқиқ қилинган. Тадқиқотларда полиуретан композицияси 60 80 °С ҳароратда 250–400 айл/мин тезликда 10–20 дақиқа давомида аралаштирилиб, кейин 0,085 0,095 МПа вакуум остида 15–30 дақиқа дегазация қилинди. Дегазация жараёнида полиуретан таркибидаги газ пуфакчалари ҳажми 92–97 % га камайиши, зичликнинг 1,08–1,12 г/см³ дан 1,14–1,18 г/см³ гача ортиши ҳамда ғовакликнинг 6,8 % дан 1,2 % гача пасайиши аниқланди. Шунингдек, дегазация жараёнидан сўнг таёрланган полиуретан материалининг Shore A/D қаттиқлиги 78/22 бирликдан 88/26 бирликкача, чўзилишдаги мустаҳкамлиги 18–22 МПа дан 28–34 МПа гача, нисбий ейилишга чидамлилиги эса 20–30 % га ошиши кузатилди. Олинган натижалар вакуумли дегазация қурилмасини қўллаш полиуретан маҳсулотларининг ички структурасини яхшилаши, ғоваклар ва ички нуқсонларни кескин камайтириши, қуйиш жараёнининг барқарорлигини ошириши ҳамда юқори мустаҳкам ва узоқ муддат хизмат қилувчи полиуретан буюмларини ишлаб чиқариш учун самарали технология эканлигини кўрсатди.
- 9 August 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (9) , 422
From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis
The cyclin-dependent kinase (CDK) family comprises one of the most common types of serine/threonine kinases responsible for controlling many cellular processes through the action of the dynamics of these enzymes. The CDKs are regulators of cellular processes, ranging from cell cycle progression, an integral step of cellular lifespan involved in its division and growth, to the expression of genes and the transfer of genetic information from DNA to RNA. CDK-related pathology is primarily based on the dysregulation of CDK, resulting in improper coordination of the cell cycle and leading to uncontrolled proliferation. The CDK1 involved in the G2 to M-phase transition interacts with CENPF, PVT1, and TFCP2L1, which affects chromosome segregation and cell proliferation. Besides the previously described partners, namely PRDX2 and C/EBPα, the CDK2 responsible for the G1/S transition has also been shown to bind TBK1 and modulate DNA synthesis and cell cycle checkpoints. Such mechanisms of action contribute to oncogenesis through interactions, including roles for lncRNAs and miRNAs in modulating the expression and activity of CDKs. Their importance in cancer has made CDK1/2 critical candidates for anticancer drug targeting. The dysregulation of CDK1/2 manifests in cancer pathology, which is, in turn, associated with an uncoordinated normal cell cycle and resultant proliferation. This study aims to provide a comprehensive overview of the diverse functions of CDK1 and CDK2 in cancer, thereby facilitating the exploration of their therapeutic potential and the development of novel cancer therapy designs. The complexity of targeting CDK1 and CDK2 highlights the importance of their regulation during cancer development. It indicates their substantial promise as valid targets for therapy, in vitro and vivo studies, and human sample analysis.
- 9 August 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (9) , 422
From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis
The cyclin-dependent kinase (CDK) family comprises one of the most common types of serine/threonine kinases responsible for controlling many cellular processes through the action of the dynamics of these enzymes. The CDKs are regulators of cellular processes, ranging from cell cycle progression, an integral step of cellular lifespan involved in its division and growth, to the expression of genes and the transfer of genetic information from DNA to RNA. CDK-related pathology is primarily based on the dysregulation of CDK, resulting in improper coordination of the cell cycle and leading to uncontrolled proliferation. The CDK1 involved in the G2 to M-phase transition interacts with CENPF, PVT1, and TFCP2L1, which affects chromosome segregation and cell proliferation. Besides the previously described partners, namely PRDX2 and C/EBPα, the CDK2 responsible for the G1/S transition has also been shown to bind TBK1 and modulate DNA synthesis and cell cycle checkpoints. Such mechanisms of action contribute to oncogenesis through interactions, including roles for lncRNAs and miRNAs in modulating the expression and activity of CDKs. Their importance in cancer has made CDK1/2 critical candidates for anticancer drug targeting. The dysregulation of CDK1/2 manifests in cancer pathology, which is, in turn, associated with an uncoordinated normal cell cycle and resultant proliferation. This study aims to provide a comprehensive overview of the diverse functions of CDK1 and CDK2 in cancer, thereby facilitating the exploration of their therapeutic potential and the development of novel cancer therapy designs. The complexity of targeting CDK1 and CDK2 highlights the importance of their regulation during cancer development. It indicates their substantial promise as valid targets for therapy, in vitro and vivo studies, and human sample analysis.